全文获取类型
收费全文 | 373390篇 |
免费 | 39696篇 |
国内免费 | 2949篇 |
专业分类
耳鼻咽喉 | 8075篇 |
儿科学 | 12084篇 |
妇产科学 | 8036篇 |
基础医学 | 35275篇 |
口腔科学 | 8684篇 |
临床医学 | 40296篇 |
内科学 | 96816篇 |
皮肤病学 | 13956篇 |
神经病学 | 32636篇 |
特种医学 | 11869篇 |
外国民族医学 | 30篇 |
外科学 | 67403篇 |
综合类 | 1346篇 |
现状与发展 | 72篇 |
一般理论 | 38篇 |
预防医学 | 31377篇 |
眼科学 | 8567篇 |
药学 | 17707篇 |
中国医学 | 862篇 |
肿瘤学 | 20906篇 |
出版年
2023年 | 5788篇 |
2022年 | 2827篇 |
2021年 | 7241篇 |
2020年 | 8161篇 |
2019年 | 6435篇 |
2018年 | 13455篇 |
2017年 | 11107篇 |
2016年 | 12320篇 |
2015年 | 12676篇 |
2014年 | 20891篇 |
2013年 | 23728篇 |
2012年 | 18677篇 |
2011年 | 19263篇 |
2010年 | 17513篇 |
2009年 | 20071篇 |
2008年 | 17158篇 |
2007年 | 16082篇 |
2006年 | 18097篇 |
2005年 | 15144篇 |
2004年 | 13552篇 |
2003年 | 11818篇 |
2002年 | 11556篇 |
2001年 | 10583篇 |
2000年 | 10339篇 |
1999年 | 9102篇 |
1998年 | 5097篇 |
1997年 | 4495篇 |
1996年 | 4319篇 |
1995年 | 4041篇 |
1994年 | 2643篇 |
1993年 | 2184篇 |
1992年 | 4466篇 |
1991年 | 4290篇 |
1990年 | 3883篇 |
1989年 | 3629篇 |
1988年 | 3296篇 |
1987年 | 2988篇 |
1986年 | 3029篇 |
1985年 | 2715篇 |
1984年 | 2018篇 |
1983年 | 1801篇 |
1979年 | 1892篇 |
1977年 | 1400篇 |
1975年 | 1429篇 |
1974年 | 1650篇 |
1973年 | 1688篇 |
1972年 | 1676篇 |
1971年 | 1526篇 |
1970年 | 1517篇 |
1969年 | 1398篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
83.
84.
Toshio Imaizumi MD PhD Toshimi Honma MD PhD Yoshifumi Horita MD Ikuhide Kohama MD PhD Kei Miyata MD Maiko Kawamura MD Jun Niwa MD PhD 《Journal of neuroimaging》2006,16(3):236-242
BACKGROUND AND PURPOSE: Dot-like low intensity spots (dot-like hemosiderin spots: dotHSs) on gradient echo T2*-weighted MRI have been histologically diagnosed to represent old cerebral microbleeds associated with microangiopathies. They have also been correlated to the fragility of small vessels and the tendency to bleed. Therefore, a substantial number of dotHSs might be associated with a large-sized, deep intracerebral hematoma (ICH). On the other hand, dotHSs may reflect old microbleeds that did not enlarge to symptomatic size. METHODS: To investigate how dotHSs are related to the size (maximal diameter) of primary deep ICH, we analyzed the diameter and the number of dotHSs in 151 patients with deep ICH not associated with subarachnoid hemorrhage or intraventricular hemorrhage (75 males and 76 females, age ranged from 37 to 90 [65.7 +/- 11.3 years old] who were consecutively admitted to Hakodate Municipal Hospital. The hazard ratio (HR) for a maximal diameter of deep ICH < or =2 cm was estimated, using the number of dotHSs and risk factors for stroke. RESULTS: The number of dotHSs associated with the diameter < or =2 cm was 9.2 +/- 11.5, significantly larger than that with the diameter > or =2 cm (4.7 +/- 7.0, P= .012). Multivariate analysis revealed that a maximal diameter of deep ICH of < or =2 cm was found in patients with dotHS (HR, 3.7; 95% confidence interval [CI], 1.4-10.1; P= .009). CONCLUSION: Though small sample size limited the power of our analyses, these findings suggest that the number of dotHSs may be associated with a small diameter of deep ICH. 相似文献
85.
86.
O Schouten J H H van Laanen E Boersma R Vidakovic H H H Feringa M Dunkelgrün J J Bax J Koning H van Urk D Poldermans 《European journal of vascular and endovascular surgery》2006,32(1):21-26
OBJECTIVE: To evaluate the effect of statins on aneurysm growth in a group of consecutive patients under surveillance for infrarenal aortic aneurysms (AAA). MATERIALS AND METHODS: All patients (59 statin users, 91 non-users) under surveillance between January 2002 and August 2005 with a follow-up for aneurysm growth of at least 12 months and a minimum of three diameter evaluations were retrospectively included in the analysis. Multiple regression analysis, weighted with the number of observations, was performed to test the influence of statins on AAA growth rate. RESULTS: During a median period of 3.1 (1.1-13.1) years the overall mean aneurysm growth rate was 2.95+/-2.8 mm/year. Statin users had a 1.16 mm/year lower AAA growth rate compared to non-users (95% CI 0.33-1.99 mm/year). Increased age was associated with a slower growth (-0.09 mm/year per year, p = 0.003). Female gender (+1.82 mm/year, p = 0.008) and aneurysm diameter (+0.06 mm/year per mm, p = 0.049) were associated with increased AAA growth. The use of non-steroidal anti-inflammatory drugs, chronic lung disease, or other cardiovascular risk factors were not independently associated with AAA growth. CONCLUSIONS: Statins appear to be associated with attenuation of AAA growth, irrespective of other known factors influencing aneurysm growth. 相似文献
87.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
88.
89.
C. M. Crceles J. M. Serrano P. Marín E. Escudero E. Fernndez‐Varn 《Transboundary and Emerging Diseases》2006,53(6):300-304
The pharmacokinetics (PK) of moxifloxacin in healthy white New Zealand rabbits was studied following intravenous (IV) and subcutaneous (SC) administration routes as well as a SC long‐acting poloxamer 407 gel formulation (SC‐P407). Moxifloxacin concentrations were determined by high‐performance liquid chromatography assay with fluorescence detection. Mean half‐life for IV, SC and SC‐P407 routes was 2.15, 5.41 and 11.09 h. Clearance value after IV dosing was 0.78 l/kg/h. After SC administration, the mean absolute bioavailability was 117% and the Cmax was 1.61 ± 0.49 mg/l. After SC‐P407 administration, the bioavailability was 44% and the Cmax 1.83 was ±0.62 mg/l. No adverse effects were observed in any of the rabbits following IV, SC and SC‐P407 administration of moxifloxacin. Minimal inhibitory concentrations of moxifloxacin against different strains of Staphylococcus aureus from different european countries were used to compute the main pharmacodynamic (PD) surrogate markers of efficacy. The high tolerability of this SC‐P407 formulation and the favourable PK behaviour such as the long half‐life, acceptable bioavailability and excellent PK–PD ratios achieved indicate that it is likely to be effective in rabbits. 相似文献
90.
Rajnish Mago MD John-Paul Gomez MD Namita Gupta MBBS Elisabeth J. S. Kunkel MD 《Current psychiatry reports》2006,8(3):228-233
Anxiety disorders and anxiety symptoms are highly prevalent in the general population and more so in the medically ill. They
have a number of negative consequences for these patients and may worsen the outcome of the medical illness and increase health
care utilization. In the evaluation of these patients, it is of paramount importance to identify the etiology of the anxiety
and, in particular, to differentiate primary from secondary anxiety. Management includes medications (especially benzodiazepines
and selective serotonin reuptake inhibitors) and psychotherapy (particularly cognitive-behavioral therapy). 相似文献